• LAST PRICE
    1.2900
  • TODAY'S CHANGE (%)
    Trending Down-0.0400 (-3.0075%)
  • Bid / Lots
    1.2700/ 1
  • Ask / Lots
    1.3400/ 6
  • Open / Previous Close
    1.3500 / 1.3300
  • Day Range
    Low 1.2500
    High 1.3500
  • 52 Week Range
    Low 1.2500
    High 17.8250
  • Volume
    573,890
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 14, 2024

  • Nov 7, 2024

      Show headlines and story abstract
    • 4:00PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: ALXO

      ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
    • 4:00PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: ALXO

      This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
  • Nov 4, 2024

Peers Headlines